scholarly journals Effect of Rhizoma Paridis saponin on the pain behavior in a mouse model of cancer pain

RSC Advances ◽  
2018 ◽  
Vol 8 (31) ◽  
pp. 17060-17072 ◽  
Author(s):  
Genbei Wang ◽  
Yuanxue Liu ◽  
Yu Wang ◽  
Wenyuan Gao
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Mouse Model ◽  
Cancer Pain ◽  
Pain Behavior ◽  
Cancer Drug ◽  
Anti Cancer

Rhizoma Paridis saponins (RPS) as active parts ofP. polyphyllaSmith var.yunnanensishas been used as an anti-cancer drug in traditional Chinese medicine.

scholarly journals In silico identification of anti-cancer compounds and plants from traditional Chinese medicine database

2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Shao-Xing Dai ◽  
Wen-Xing Li ◽  
Fei-Fei Han ◽  
Yi-Cheng Guo ◽  
Jun-Juan Zheng ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Cancer Drug ◽  
Cancer Drugs ◽  
Supportive Role ◽  
Starting Point ◽  
Anti Cancer ◽  
Approved Drugs ◽  
Alternative Resource

Abstract There is a constant demand to develop new, effective, and affordable anti-cancer drugs. The traditional Chinese medicine (TCM) is a valuable and alternative resource for identifying novel anti-cancer agents. In this study, we aim to identify the anti-cancer compounds and plants from the TCM database by using cheminformatics. We first predicted 5278 anti-cancer compounds from TCM database. The top 346 compounds were highly potent active in the 60 cell lines test. Similarity analysis revealed that 75% of the 5278 compounds are highly similar to the approved anti-cancer drugs. Based on the predicted anti-cancer compounds, we identified 57 anti-cancer plants by activity enrichment. The identified plants are widely distributed in 46 genera and 28 families, which broadens the scope of the anti-cancer drug screening. Finally, we constructed a network of predicted anti-cancer plants and approved drugs based on the above results. The network highlighted the supportive role of the predicted plant in the development of anti-cancer drug and suggested different molecular anti-cancer mechanisms of the plants. Our study suggests that the predicted compounds and plants from TCM database offer an attractive starting point and a broader scope to mine for potential anti-cancer agents.

Could COVID-19 Cause ‘Biopharming’ to Bloom?

2020 ◽  
Vol 25 (3) ◽  
Author(s):  
Kathleen Hefferon ◽  
Henry Miller ◽  
Henry Miller
Keyword(s):  
Carbon Dioxide ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Raw Materials ◽  
Cancer Drug ◽  
The Sun ◽  
Flexible Production ◽  
Cost Cutting ◽  
Anti Cancer ◽  
Production Techniques

At an accelerated rate in response to the COVID-19 pandemic, academic and corporate scientists are using genetic engineering techniques to reprogram plants to produce significant concentrations of high-value pharmaceuticals. The concept is not new. Many common medicines, such as certain opiates, the laxative Metamucil, and the anti-cancer drug Taxol, are all purified from plants, and efficacy has been shown for some herbals in Traditional Chinese Medicine. There is great potential for cost-cutting in the process: The energy for product synthesis comes from the sun, and the primary raw materials are water and carbon dioxide. In addition, biopharming offers tremendous flexibility and economy when adjustments in production are necessary. The need for inexpensive, flexible production techniques for COVID-19 therapeutics and vaccines could be a potent stimulus to biopharming research and development.

scholarly journals Evaluation of the anti-cancer activity of the triterpenoidal saponin fraction isolated from the traditional Chinese medicine Conyza blinii H. Lév.

RSC Advances ◽  
2017 ◽  
Vol 7 (6) ◽  
pp. 3408-3412 ◽  
Author(s):  
Long Ma ◽  
Haiyan Liu ◽  
Lingpei Meng ◽  
Ping Qin ◽  
Botao Zhang ◽  
...  
Keyword(s):  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Anti Cancer ◽  
Saponin Fraction ◽  
Cancer Activity

Triterpenoidal saponins fraction isolated from a traditional Chinese medicine Conyza blinii H. Lév. demonstrates anti-cancer activity both in vitro and in vivo.

scholarly journals Tubeimoside-1 Inhibits Glioblastoma Growth, Migration, and Invasion via Inducing Ubiquitylation of MET

Cells ◽  
2019 ◽  
Vol 8 (8) ◽  
pp. 774 ◽  
Author(s):  
Jiangjun Cao ◽  
Erhu Zhao ◽  
Qingzong Zhu ◽  
Juanli Ji ◽  
Zekun Wei ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Chinese Medicine ◽  
Cell Growth ◽  
Traditional Chinese Medicine ◽  
Receptor Tyrosine Kinase ◽  
Protein Level ◽  
Migration And Invasion ◽  
Anti Cancer ◽  
Inhibit Cell Growth ◽  
Receptor Tyrosine Kinase Family

Tubeimoside-1 (TBMS1) is one of the extracts of rhizoma bolbostemmae, which has remarkable anti-cancer function in the treatment of esophagus and gastric cancer in traditional Chinese medicine. However the mechanisms of its anti-cancer function is remain unclear. In this study, we demonstrate that TBMS1 could inhibit cell growth and metastasis in glioblastoma. MET is a member of the receptor tyrosine kinase family, which amplifies frequently in various human cancers. As an important proto-oncogene, multiple inhibitors have been developed for the therapy of cancers. Here, we found TBMS1 could reduce/decrease the protein level of MET via increasing its Ubiquitination degradation. Therefore, TBMS1 is a promising compound for the treatment of glioblastoma and an inhibitor of MET.

Establishment of Bioluminescence Imaging Based Leukemia In Vivo Model for Preclinical Testing

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4879-4879
Author(s):  
Myoung Woo Lee ◽  
Hye Jin Kim ◽  
Dae Seong Kim ◽  
Meong Hi Son ◽  
Soo Hyun Lee ◽  
...  
Keyword(s):  
Animal Model ◽  
Mouse Model ◽  
Drug Screening ◽  
Scid Mouse ◽  
Lymphoblastic Leukemia ◽  
Cancer Drug ◽  
Screening System ◽  
Bioluminescent Signal ◽  
Anti Cancer

Abstract Abstract 4879 Background. A hematological malignant animal model is an essential tool for evaluating efficacy of anti-cancer drugs and elucidating underlying mechanism of leukemogenesis. Intraperitoneal (IP) and intravenous (IV) xenograft of acute lymphoblastic leukemia (ALL) cells have limited capacity as in vivo anti-cancer drug screening system. Purpose. In this study, we aimed to establish an ALL animal model using NOD/SCID mouse and evaluate efficiency and sensitivity of the model as a preclinical drug screening system. Materials and Methods. Firefly luciferase (fLuc)-gene introduced ALL (ALL/fLuc) cell line and patient-originated ALL cells were transplanted into a tibia of NOD/SCID mouse. We conducted a comparative analysis of intra-bone marrow (IBMT) transplanted leukemia model with IP and IV transplantation of leukemic cells. Results. IBMT of ALL/fLuc cells effectively established a bioluminescent leukemia NOD/SCID mouse model. Upon comparison of IBMT model with IP and IV transplantation models, infusing identical number of ALL/fLuc cells into NOD/SCID mice resulted in IBMT model with evaluable bioluminescent signal, but not in IP and IV models. In IBMT model, bioluminescent signals of ALL/fLuc cells emitted from peripheral blood, tibia and infiltrated organs indicated that leukemia model was established. The changes in these signals' strength reflected dose-dependent cytotoxic effects of vincristine, which allowed leukemia model with evaluable bioluminescent signal to be utilized as a preclinical drug screening system. IBMT leukemia model was also established using primary ALL cells that can provide additional insights for the development of leukemia therapeutics. Conclusion. IBMT of ALL/fLuc cells enables development of leukemia mouse model with the greater bioluminescent sensitivity than IP and IV in NOD/SCID to evaluate candidate for development of anti-cancer drug. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document